Actelion to shed 135 jobs in cost-cutting drive

Here's another example of what competition can do to a drugmaker. Sales of Actelion's ($ATLN) top product, the blood pressure drug Tracleer, are faltering, so the Swiss company is planning to slash 135 jobs and refocus its R&D. Report